What synlab Eesti OÜ does

SYNLAB Eesti OÜ is the Estonian operating subsidiary of the pan-European SYNLAB Group, one of Europe's largest medical diagnostic laboratory networks (the parent is held by the A.P. Møller group following its acquisition from Cinven and other investors). The company provides medical diagnostic laboratory services across Estonia, spanning clinical chemistry, hematology, immunology, microbiology, molecular diagnostics, and genetic testing, including a flagship pharmacogenetics DNA panel that analyses 34 genes to predict drug metabolism for approximately 300 active pharmaceutical ingredients across 13 therapeutic areas. The pharmacogenetics panel runs on OpenArray and CNV analysis from EDTA blood or buccal swab samples with a 21 working-day turnaround, and is offered both to physicians (via integrated electronic ordering at 315 EUR under TK codes 66616/66610) and to private customers (at 325 EUR).

The business serves three primary customer segments with distinct go-to-market motions. Healthcare professionals (doctors, general practitioners, specialists) order electronically through Estonian physician software systems (Perearst2, Perearst3, LIISA, eKliinik, Watson/Winston, Ester/Heda, MIS) connected via the Medipost data exchange platform, with billing processed through health insurance reimbursement codes. Private individuals purchase tests directly through the Minu SYNLAB e-commerce portal (ee.minu.synlab.ee), which organises offerings into General Health, Nutrition, Sexual Health, Sport, Children, and "Test Yourself" home sampling categories, with sample collection available at nationwide phlebotomy points or via the mobile SYNLAB Bus. Employers are served through occupational health checks and corporate health days. SYNLAB Eesti also conducts scientific collaborations with the University of Tartu (KoroSero-EST seroepidemiological studies on 3,283 and 2,517 samples; KoroGeno-EST SARS-CoV-2 whole-genome sequencing) and the Health Development Institute on STI prevalence and nutrition biomarker studies, holds ISO 14001:2015 environmental certification, and maintains a patient insurance contract with Lloyd's Insurance Company S.A. (100,000 EUR per entitled person; 3,000,000 EUR per insurance period, valid 01.12.2025–30.11.2026).

Name

synlab Eesti OÜ

Legal name

SYNLAB Eesti OÜ

Website

https://synlab.ee

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

1–10 employees

Short description

SYNLAB Eesti OÜ is the Estonian subsidiary of the pan-European SYNLAB Group, operating a nationwide medical diagnostic laboratory network that serves healthcare professionals (via integrated EHR ordering), private consumers (via the Minu SYNLAB e-commerce portal and SYNLAB Bus), and employers (occupational health services).

Ownership category

akta.pro rank

Product category

Medical Diagnostic Laboratory Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Reference & Esoteric Testing Laboratories (HLAFAMAJ)

akta.pro secondary industries

Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

Keywords

• Medical diagnostic services
• Pharmacogenetics testing
• Clinical laboratory analysis
• Genetic health panels
• Occupational health screening

Headquarters

HQ city

Tallinn

HQ country

Estonia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Clinical Laboratory Testing Services: Laboratory testing services for healthcare providers including clinical chemistry, hematology, immunology, microbiology, and genetic analyses. Revenue generated through health insurance reimbursements and direct patient/employer payments. Tests are billed using TK codes (e.g., 66616, 66610).
2. Direct-to-Consumer Genetic Testing: Private individuals purchase genetic tests directly through the Minu SYNLAB e-commerce platform including pharmacogenetics panels (325 EUR), microbiome tests (212 EUR), and other health panels. Results delivered via secure patient portal.
3. Occupational Health Services: Pre-employment and preventive health check services for employers ( tööandjale ). Companies engage SYNLAB for workplace health assessments and organized health days.
4. Healthcare Professional Services: Laboratory testing for medical professionals with electronic ordering through integrated physician software systems (Perearst2, Perearst3, LIISA, eKliinik, Watson/Winston, Ester/Heda, MIS).
5. Genetic Report Interpretation: Interpretation service for pharmacogenetic test results available at 26 EUR, providing clinical guidance based on genetic profiles.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Core offering

SYNLAB Eesti OÜ operates a medical diagnostic laboratory network in Estonia, providing clinical testing services to healthcare providers and private patients. Core offerings span clinical chemistry, hematology, immunology, microbiology, molecular diagnostics, genetic testing, and a flagship 34-gene pharmacogenetics DNA panel for personalized medication selection covering approximately 300 active pharmaceutical ingredients. Services are delivered through physical blood collection points, a mobile SYNLAB Bus, an electronic physician ordering platform, and the direct-to-consumer Minu SYNLAB portal.

Product overview

SYNLAB Eesti OÜ operates a medical diagnostic laboratory network providing clinical testing services to healthcare providers and private patients across Estonia. The core offering is organized around the Minu SYNLAB self-service portal (ee.minu.synlab.ee) for patients, and a physician-facing service platform (synlab.ee/arstile) for healthcare professionals who order tests electronically. The Minu SYNLAB portal distributes testing across several consumer-facing service categories — General Health (Üldtervis), Nutrition (Toitumine), Sexual Health (Seksuaaltervis), Sport, Children (Lapsed) — alongside a 'Test Yourself' (TESTI ISE) home sampling option, consultation services, and gift cards. The flagship clinical product is the Farmakogeneetika DNA paneel, a pharmacogenetics panel that analyzes 34 genes to guide personalized drug selection and dosing across ~300 active pharmaceutical ingredients in 13 therapeutic areas. SYNLAB also maintains a molecular biology laboratory for pharmacogenetics testing, blood collection points throughout Estonia, a SYNLAB Bus mobile sampling service, and a training center (Koolituskeskus) for professional education.

Differentiator

Problem solved

Functional benefit

Products and services

• Farmakogeneetika DNA paneel (Pharmacogenetics DNA Panel) A DNA-based pharmacogenetics panel analyzing 34 genes to predict patient drug metabolism phenotypes and guide personalized selection and dosing of approximately 300 active pharmaceutical ingredients across 13 therapeutic areas (dermatology, respiratory, anti-infectives, cardiovascular, oncology, sensory organs, neurology, parasitology, gastrointestinal, musculoskeletal, hormones, genitourinary, blood). The test uses OpenArray and CNV analysis from EDTA blood or buccal swab samples with results delivered in 21 working days. Available to physicians via electronic prescribing systems integrated with Medipost and to private patients through Minu SYNLAB.
• Minu SYNLAB Patient Self-Service Portal A web-based self-service portal (ee.minu.synlab.ee) through which private patients can purchase individual tests and health packages, schedule sample collection appointments at SYNLAB phlebotomy points or the SYNLAB Bus, access test results, and book physician consultations. The portal organizes services into categories: General Health, Nutrition, Sexual Health, Sport, Children, and 'Test Yourself' (TESTI ISE) home sampling kits. A separate Minu SYNLAB results viewer (results.minu.synlab.ee) delivers test results with explanatory content.

Quantifiable outcome

• SARS-CoV-2 antibodies persist in approximately 80% of individuals 6-8 months after asymptomatic COVID-19
• +2 more outcomes

Named customers9 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Estonian Olympic Committee (Eesti Olümpiakomitee)coreStrategic or Co-development PartnerSYNLAB provides free COVID-19 testing for Team Estonia Olympic athletes preparing for Summer and Winter Olympic Games, supporting their competitive preparation.
• Estonian Paralympic Committee and Special Olympics EstoniacoreStrategic or Co-development PartnerFree COVID-19 testing services for Paralympic and Special Olympics athletes to enable their participation in international competitions.
• Health Development Institute (Tervise Arengu Instituut)coreStrategic or Co-development PartnerMultiple cooperation projects on sexually transmitted infection prevalence studies in risk groups, HIV testing and counseling in Tallinn and Tartu, and nutrition research including vegetarian and salt consumption studies.
• University of Tartu - Institute of Biomedicine and Translational MedicinecoreStrategic or Co-development PartnerSeroepidemiological studies KoroSero-EST (1-3) analyzing SARS-CoV-2 antibody prevalence and KoroGeno-EST whole genome sequencing research. SYNLAB provides laboratory analysis of blood samples and contributes expertise.
• Estonian Association of Performing Arts Organizations (Eesti Etendusasutuste Liit)minorStrategic or Co-development PartnerFree COVID-19 testing for actors, musicians, and cultural professionals to enable virus-free cultural events in Estonia.
• SportEST - Movement Health Innovation ClusterminorStrategic or Co-development PartnerPartner in sports medicine development including training, conferences, new service development, and health awareness activities in Estonia.
• SOS Children's Village Estonia (SOS Lasteküla Eesti Ühing)minorStrategic or Co-development PartnerAnnual free health checks provided for all substitute parents, supporting the organization's family care mission.
• Estonian Sports Federations (Swimming, Biathlon, Skiing, Triathlon)minorStrategic or Co-development PartnerResearch on elite athletes' blood markers, free laboratory analyses, and laboratory physician consultations supporting Estonian sports development.
• Society of STI (STLIEÜ)minorStrategic or Co-development PartnerCooperation on conferences and field development events for sexual health and STI prevention in Estonia.
• Social Insurance Board (Sotsiaalkindlustusamet)minorStrategic or Co-development PartnerPartnership to support nursing homes with donations of tablet computers and specialized mattresses for residents.
• Medipost Data Exchange PlatformcoreTechnology or IntegrationTechnology integration enabling electronic test ordering and results delivery through physician software systems (Perearst2, Perearst3, LIISA, eKliinik, Watson/Winston, Ester/Heda, MIS).

Scale indicators5 records

Recent moves6 records

Expansion highlights7 records

Emerging players

• LetsGetChecked: LetsGetChecked is a DTC diagnostics company offering home self-collection kits, online ordering, and digital result delivery across multiple European markets. Its consumer-driven model and home-sampling logistics directly parallel SYNLAB Eesti's Minu SYNLAB portal and TESTI ISE home-sampling service.
• Helix: Helix operates a population genomics and clinical-grade genetic testing platform with a focus on pharmacogenomics and consumer-driven health insights. It is a relevant emerging comparable for SYNLAB Eesti's DTC and pharmacogenetics positioning, particularly as personalized medicine adoption scales.

Broad incumbents

• Cerba Healthcare: Cerba Healthcare is a European clinical laboratory network focused on specialty and esoteric testing across multiple countries. Its emphasis on advanced diagnostics, reference testing, and hospital partnerships makes it a relevant comparable for SYNLAB Eesti's higher-margin esoteric and pharmacogenetics services.
• Medicover: Medicover operates integrated diagnostic laboratory and healthcare services across Central and Eastern Europe, including the Baltics and Nordics. Its regional diagnostic service offering, employer health programs, and DTC consumer channels directly overlap with SYNLAB Eesti's three-segment model in adjacent geographies.
• Eurofins Genomics: Eurofins is a global laboratory testing group with strong European presence across clinical diagnostics, genetics, and biomarker testing. It competes with SYNLAB Eesti for advanced esoteric and genomic testing referrals and provides a comparable reference for assay menu breadth and scientific service positioning.

Direct peers

• Unilabs: Unilabs is one of Europe's largest clinical laboratory and diagnostic networks, operating in 16+ countries with a comparable menu of clinical chemistry, genetics, pharmacogenetics, and specialty testing. It is the most direct pan-European competitor to SYNLAB and a key reference for cross-border testing and esoteric service positioning.
• Synlab Finland: Synlab Finland is the Finnish sibling subsidiary of SYNLAB Eesti within SYNLAB Group. It operates the same clinical chemistry, immunology, genetics, and pharmacogenetics service portfolio for healthcare providers and private customers in Finland, making it the closest functional and operational comparable for benchmarking the Estonian entity.
• SYNLAB Group: SYNLAB Group is the direct parent company of SYNLAB Eesti and operates one of Europe's largest medical diagnostic laboratory networks across ~30 countries. The Group's centralized assay development, reference testing capabilities, and pan-European commercial platform are directly leveraged by SYNLAB Eesti for its esoteric and routine diagnostic offerings.

Regional players

• Tartu University Hospital Laboratory: Tartu University Hospital operates one of Estonia's largest in-hospital clinical laboratories, providing routine and specialty testing primarily within the public healthcare system. It is the principal domestic institutional competitor for physician-ordered diagnostic volume in Estonia.
• North Estonia Medical Centre (PERH) Laboratory: North Estonia Medical Centre operates a major hospital-based clinical laboratory in Tallinn serving the largest Estonian hospital catchment area. It is a primary institutional competitor to SYNLAB Eesti for public and hospital-channel diagnostic testing in the capital region.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks1 record

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about synlab Eesti OÜ